Announcements Trials

Browse Landscape

Phase

Phase 4 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Myasthenia Gravis 1 Leukemia 1 Drug-Related Side Effects and Adverse Reactions 1

Interventions

rozanolixizumab 7 zilucoplan 6 efgartigimod alfa 5 eculizumab 4 telitacicept 3 ravulizumab 3 Tacrolimus 3 Rituximab 3 Amifampridine 3 Prednisone 2 Mycophenolic Acid 2 HBM9161 2 satralizumab 1 remibrutinib 1 iptacopan 1 inebilizumab 1 Thymectomy 1 Sugars 1 Steroids 1 Sodium Chloride 1 Pyridostigmine Bromide 1 Prednisolone 1 Plasmapheresis 1 Leflunomide 1 Immunoglobulins, Intravenous 1 Hizentra 1 Cladribine 1 Azathioprine 1 Alkalies 1 Adrenal Cortex Hormones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Myasthenia Gravis × Pyridostigmine Bromide × Clear all

NCT05919407 2023-06-26

IMPACT-MG

Leiden University Medical Center

Phase 3 Unknown

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡